stockrow
Friday 6 November 2026
Export MDXG’s income statement to Excel — free account
MiMedx Group, Inc
MDXG Healthcare Biotechnology
MiMedx Group, Inc’s revenue for fiscal 2025 (year ended December 2025) was $418.6 million, up 20.0% from fiscal 2024.
- Revenue
- −45.2%
- EPS
- −154.1%
- Free cash flow
- −87.2%
- Total debt
- −6.80%
Quarter to September 2026, against a year earlier
3.31
0.03
+0.91%
Follow MDXG
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 222 | 321 | 359 | 299 | 248 | 242 | 268 | 321 | 349 | 419 | 304 | +7.3% | 257 | 306 | 387 | (2.6%) | |
| Gross margin, % | 86.05 | 89.03 | 89.87 | 85.60 | 84.16 | 83.63 | 81.96 | 83.01 | 82.78 | 82.56 | 77.29 | (3.5) pt | ||||||
| EBT | 1 | 45 | (3) | (26) | (62) | (12) | (20) | 31 | 57 | 66 | (22) | +70.5% | ||||||
| EBT margin, % | 0.25 | 14.04 | (0.95) | (8.55) | (24.79) | (4.98) | (7.37) | 9.53 | 16.42 | 15.83 | (7.37) | +15.6 pt | ||||||
| Net income | 0 | 65 | (30) | (26) | (49) | (12) | (20) | 67 | 42 | 49 | (19) | +70.9% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 2.09 | 3.03 | 3.40 | 2.80 | 2.29 | 2.19 | 2.37 | 2.76 | 2.37 | 2.83 | 2.08 | +3.4% | |||||
| Earnings | 0.00 | 0.58 | (0.28) | (0.23) | (0.77) | (0.15) | (0.33) | 0.40 | 0.29 | 0.33 | (0.13) | +64.7% | ||||||
| Cash flow | 0.23 | 0.59 | 0.34 | (0.37) | (0.28) | (0.02) | (0.16) | 0.23 | 0.45 | 0.50 | 0.14 | +9.3% | ||||||
| Capex | (0.07) | (0.05) | (0.09) | (0.02) | (0.04) | (0.03) | (0.01) | (0.02) | (0.01) | (0.01) | (0.01) | (22.1%) | ||||||
| Free cash flow | 0.16 | 0.54 | 0.24 | (0.39) | (0.32) | (0.05) | (0.17) | 0.21 | 0.44 | 0.49 | 0.13 | +13.4% | ||||||
| Book value | 1.26 | 0.70 | 0.47 | 0.32 | 0.00 | 0.00 | (0.16) | 1.23 | 1.31 | 1.74 | 1.45 | +3.7% | ||||||
| Shares, m | 106 | 106 | 106 | 107 | 108 | 110 | 113 | 116 | 147 | 148 | 147 | +3.8% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 3,650.00 | 21.28 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.68 | 34.36 | 20.52 | 0.00 | 374.6 | |||||
| P/S | 4.19 | 4.29 | 0.53 | 2.71 | 3.96 | 2.75 | 1.25 | 2.85 | 4.05 | 2.39 | 1.59 | 2.9 | ||||||
| P/B | 6.98 | 18.67 | 3.81 | 23.57 | 0.00 | 8,128.44 | 0.00 | 6.42 | 7.32 | 3.90 | 2.29 | 819.9 | ||||||
| EV/Sales | 4.03 | 4.20 | 0.40 | 2.70 | 3.77 | 2.60 | 1.19 | 2.75 | 3.81 | 2.04 | 1.25 | 2.7 | ||||||
| EV/FCF | 53.18 | 23.46 | 5.58 | (19.39) | (26.88) | (115.34) | (16.46) | 35.66 | 20.59 | 11.68 | 19.94 | (2.8) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | 24 | 63 | 36 | (39) | (30) | (2) | (18) | 27 | 66 | 74 | 21 | +13.4% | |||||
| Capex | (7) | (5) | (10) | (2) | (5) | (3) | (2) | (2) | (2) | (1) | (2) | (19.2%) | ||||||
| Free cash flow | 17 | 58 | 26 | (42) | (35) | (5) | (19) | 25 | 65 | 73 | 19 | +17.7% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 76 | 3 | 3 | 56 | 101 | 106 | 91 | 118 | 146 | 213 | 144 | +12.2% | |||||
| Net debt | (34) | (27) | (45) | (3) | (47) | (38) | (16) | (33) | (86) | (148) | (121) | +17.6% | ||||||
| Shareholders’ equity | 133 | 74 | 50 | 34 | 0 | 0 | (18) | 143 | 193 | 257 | 211 | +7.6% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | 0.24 | 41.16 | (24.56) | (17.64) | (45.14) | (8.42) | (20.47) | 28.37 | 16.87 | 16.02 | (6.58) | +15.8 pt | |||||
| ROIC | 0.56 | 61.99 | (51.46) | (42.68) | 0.00 | 0.00 | 0.00 | 21.12 | 34.22 | 36.84 | (17.40) | +36.3 pt | ||||||
| ROE | 0.32 | 62.60 | (48.57) | (60.87) | (486.62) | 48,297.06 | 410.78 | 93.37 | 25.26 | 21.61 | (8.53) | +21.3 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 690 | — | 753 | 696 | 735 | 811 | 867 | 895 | 837 | 808 | — | +1.8% | |||||
| Revenue/emp, $m | 0.32 | 0.00 | 0.48 | 0.43 | 0.34 | 0.30 | 0.31 | 0.36 | 0.42 | 0.52 | — | +5.5% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 2 Nov 2026
MiMedx Group, Inc vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| OVID Ovid Therapeutics | $503.9M | — (loss-making) | — (loss-making) | +463.85% (above 0%: growing) | n/m | −268.54% (below 0%: shrinking) | 100.00% | (2,141.61%) | Compare |
| CAPR Capricor Therapeutics, Inc. | $500.0M | — (loss-making) | — (loss-making) | −7.92% (below 0%: shrinking) | n/m | −72.88% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| DMAC DiaMedica Therapeutics, Inc. | $487.5M | — (loss-making) | — (loss-making) | — | n/m | −6.75% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| RGNX REGENXBIO Inc. | $487.2M | — (loss-making) | — (loss-making) | −69.19% (below 0%: shrinking) | n/m | +168.05% (above 0%: growing) | 87.55% | (387.84%) | Compare |
| INDP Indaptus Therapeutics, Inc. | $485.3M | — (loss-making) | — | — | n/m | +52.03% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CBIO Crescent Biopharma, Inc. | $480.6M | — (loss-making) | — (loss-making) | +1,038,900.00% (above 0%: growing) | n/m | −7.04% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| MDXG MiMedx Group, Inc | $478.6M | — (loss-making) | — (loss-making) | −45.23% (below 0%: shrinking) | n/m | −87.21% (below 0%: shrinking) | 79.80% | (18.79%) | |
| CTMX CytomX Therapeutics, Inc. | $466.3M | — (loss-making) | — (loss-making) | −71.69% (below 0%: shrinking) | n/m | +204.14% (above 0%: growing) | 100.00% | (1,392.30%) | Compare |
| ETRA Electra Therapeutics Inc. | $461.3M | — | — | — | — | — | — | — | Compare |
| Median of peers | $486.3M | — | — | −7.92% | — | −6.75% | 100.00% | 0.00% |